Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in August 2010 on request of the sponsor.
On 4 August 2010, orphan designation (EU/3/10/763) was granted by the European Commission to Allergan Pharmaceuticals Ireland, Ireland, for dexamethasone (intravitreal implant) for the treatment of non-infectious uveitis affecting the posterior segment (the back) of the eye.
Treatment of non-infectious uveitis affecting the posterior segment of the eye
|Orphan designation status||
|EU designation number||
|Date of designation||
Allergan Pharmaceuticals Ireland
Telephone: +353 98 55 201
Telefax: +353 98 25 791
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: